Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.
Adult
Aged
Antibodies, Bacterial
/ blood
Antigens, Bacterial
/ immunology
Bacterial Proteins
/ immunology
Case-Control Studies
Chlamydia Infections
/ complications
Chlamydia trachomatis
/ immunology
Female
Follow-Up Studies
Humans
Middle Aged
Ovarian Neoplasms
/ epidemiology
Poland
/ epidemiology
Prognosis
Prospective Studies
Risk Factors
United States
/ epidemiology
Young Adult
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
09
01
2018
revised:
20
03
2018
accepted:
03
04
2018
pubmed:
24
5
2018
medline:
12
3
2020
entrez:
24
5
2018
Statut:
ppublish
Résumé
Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations. Studies included: 1) a case-control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case-control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression. In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR = 2.00, 95% CI = 1.38 to 2.89; cut-point 3 [max OR]: OR = 2.19, 95% CI = 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR = 1.43, 95% CI = 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR = 2.25, 95% CI = 1.07 to 4.71); cut-point 3: OR = 2.53, 95% CI = 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk. In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer.
Sections du résumé
BACKGROUND
Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations.
METHODS
Studies included: 1) a case-control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case-control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression.
RESULTS
In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR = 2.00, 95% CI = 1.38 to 2.89; cut-point 3 [max OR]: OR = 2.19, 95% CI = 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR = 1.43, 95% CI = 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR = 2.25, 95% CI = 1.07 to 4.71); cut-point 3: OR = 2.53, 95% CI = 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk.
CONCLUSIONS
In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer.
Identifiants
pubmed: 29790947
pii: 5001107
doi: 10.1093/jnci/djy084
pmc: PMC6376903
doi:
Substances chimiques
Antibodies, Bacterial
0
Antigens, Bacterial
0
Bacterial Proteins
0
pgp3 protein, Chlamydia
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-136Informations de copyright
Published by Oxford University Press 2018.
Références
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
pubmed: 10469746
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
pubmed: 11189684
Infect Immun. 2001 Apr;69(4):2442-7
pubmed: 11254605
Cancer Causes Control. 2001 May;12(4):335-41
pubmed: 11456229
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
J Infect Dis. 2003 Apr 1;187(7):1147-52
pubmed: 12660930
Br J Cancer. 2003 Aug 18;89(4):672-5
pubmed: 12915876
Cell Mol Life Sci. 2005 Jan;62(1):4-9
pubmed: 15619002
Epidemiology. 2005 Jul;16(4):500-7
pubmed: 15951668
Mutat Res. 2005 Dec 30;592(1-2):147-54
pubmed: 16054167
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
Eur J Gynaecol Oncol. 2005;26(6):642-5
pubmed: 16398227
Sex Transm Dis. 2006 Dec;33(12):747-52
pubmed: 16691155
BMC Cancer. 2007 Apr 05;7:60
pubmed: 17411440
Am J Public Health. 2007 Jun;97(6):1118-25
pubmed: 17463380
Eur J Gynaecol Oncol. 2007;28(2):117-20
pubmed: 17479672
Int J Gynecol Pathol. 2008 Jan;27(1):18-23
pubmed: 18156969
Infect Dis Obstet Gynecol. 2008;2008:219672
pubmed: 19125176
Am J Obstet Gynecol. 2010 Jan;202(1):71.e1-6
pubmed: 19766974
Hum Pathol. 2011 Jul;42(7):918-31
pubmed: 21683865
Infect Dis Obstet Gynecol. 2011;2011:824627
pubmed: 21811380
Lancet Oncol. 2011 Sep;12(9):900-4
pubmed: 21835693
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2311-7
pubmed: 22402815
Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34
pubmed: 22543918
J Virol. 2013 Aug;87(16):8916-26
pubmed: 23740984
Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35
pubmed: 24131966
Infect Dis Clin North Am. 2013 Dec;27(4):793-809
pubmed: 24275271
Gynecol Oncol. 2014 Nov;135(2):297-304
pubmed: 25158036
Sex Transm Infect. 2015 Dec;91(8):589-91
pubmed: 25921018
N Engl J Med. 2015 May 21;372(21):2039-48
pubmed: 25992748
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1360-5
pubmed: 26169147
Am J Epidemiol. 2016 Jan 1;183(1):61-9
pubmed: 26667254
Am J Epidemiol. 2016 Apr 1;183(7):671-9
pubmed: 26968942
PLoS One. 2016 Mar 14;11(3):e0151497
pubmed: 26974653
Am J Epidemiol. 2016 May 1;183(9):800-14
pubmed: 27190045
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
J Immunol Methods. 2017 Jun;445:23-30
pubmed: 28283408
Cancer Causes Control. 2017 May;28(5):415-428
pubmed: 28342087
Infect Agent Cancer. 2017 May 18;12:25
pubmed: 28529540
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 29117355
Fertil Steril. 1987 Jan;47(1):118-21
pubmed: 3792565
Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):447-51
pubmed: 7549798
Proc Natl Acad Sci U S A. 1993 May 1;90(9):3998-4002
pubmed: 8387206
Gynecol Oncol. 1996 Nov;63(2):258-60
pubmed: 8910637